Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
4,803 total articles
Monolithic Power Systems (MPWR) posts impressive profitability and cash generation, but the shares trade at a premium (roughly 82x EPS, ~18.6x sales) with momentum faltering. For traders willing to accept higher risk, a mid-term short (45 trading days) targeting a meaningful mean reversion offers an asymmetric trade: the fundamentals cushion downsi…
Nebius appears to have moved from concept to commercial runway after a high-profile Nvidia endorsement. That validation should open customer doors and accelerate revenue cadence, but the stock is a trade, not a buy-and-forget. We outline a mid-term swing trade with a clear entry, stop, and target, and the operational milestones that should drive th…
QuantumScape's engineering story has improved: QSE-5 samples, strategic supplier deals, and an Eagle pilot line move the company from lab promises closer to manufacturing reality. The stock, trading at $7.03 with a $4.29B market cap, still needs commercial-scale manufacturing proof. This trade idea buys the improved narrative while protecting capit…
Automatic Data Processing (ADP) is a Dividend King trading near its 52-week low with a 2.9% yield, $4.6B in free cash flow and a P/E of ~20.7. Weak near-term labor data and AI worries have driven the price lower, creating a defined-risk long trade targeting a valuation re-rate and steady cash return drivers.
Constellation Brands (STZ) looks like an actionable long trade as the company navigates a transitional 2026. The shares have pulled back from last year’s highs, valuation metrics (EV/EBITDA ~10.9x, P/E ~23.5x) are not demanding given $1.76B in free cash flow and a $26.1B market cap, and Berkshire Hathaway's interest plus recent beats create a favor…
Pagaya Technologies combines AI-driven credit underwriting with an asset-light pivot that has materially improved cash generation. At roughly 4x price-to-free-cash-flow and a market cap under $1.0B, the stock looks like a GARP (growth at a reasonable price) candidate. This trade idea outlines an entry, stop, targets, catalysts and balanced risks fo…
Hims & Hers (HIMS) just turned a legal liability into leverage: the Novo Nordisk partnership announced in early March resolved a major lawsuit and restores GLP-1 access to HIMS' telehealth channel. The stock is trading near $26.62 after a big gap; fundamentals still show strong revenue traction ($619M quarterly) and management targets $2.8B for 202…
Inspire Medical (INSP) is a leader in implantable therapy for obstructive sleep apnea. After a bruising product rollout and legal headlines, the balance sheet and cash flow remain intact, valuation is accessible and technical indicators show oversold conditions. This trade idea buys a recovery driven by improved billing, provider training completio…
Dell just reported blockbuster AI server results and laid out aggressive AI revenue targets. The stock has momentum, solid free cash flow, and valuation that still looks reasonable relative to the growth profile. This trade plan targets participation in the AI-led re-rating with defined entry, stop, and target levels and a long-term horizon of 180 …
NextEra Energy combines a regulated utility (FPL) and a massive renewable generation business (NEER). With a $190B market cap, meaningful free cash flow and a mid-20s PE, the setup is attractive for a long trade into the next 180 trading days. This idea lays out five structural positives, concrete valuation framing, catalysts, and an actionable ent…
Workday is caught between negative headlines about AI-driven SaaS disruption and a durable, cash-generative business with high switching costs. With a market cap near $37B, $2.78B in free cash flow and price-to-sales of ~3.9x, the stock is an actionable mid-term long as investors reprice durable revenue and AI investments. Entry $143.00, target $17…
Regeneron (REGN) has rallied hard from its 2025 lows and now trades at roughly $770 with a market cap near $81.3B. Fundamentals - a $42.61 EPS, healthy free cash flow and low leverage - support the premium multiple, but much of the upside is already reflected in the price. This trade idea recommends a disciplined, mid-term long on a measured pullba…
Owlet (OWLT) tumbled after a 03/09/2026 outlook that trimmed Q1 revenue expectations to $20-21M versus consensus near $26.2M. The move pushed the shares to $6.10 and left the stock deeply oversold (RSI ~21). With a market cap of roughly $168M, an enterprise value near $147M, and recent revenue momentum (Q4 revenue $26.6M, +29.6% Y/Y), this is a hig…
NextEra Energy is trading near $91.69 with a valuation that, on several metrics, sits below its own recent trading history. Solid free cash flow ($3.77B), a 2.5% dividend yield, and exposure to secular tailwinds - renewables and data-center demand - support a constructive, actionable long trade with defined risk.
Qualcomm (QCOM) is trading like a broken company after a sharp drop from the 52-week high of $205.95 to $135.20. Fundamentals tell a different story: $12.9B free cash flow, 23% ROE, and a $144B market cap. With an oversold technical backdrop, rising short interest and strong cash generation, this is a tactical long where upside from a normalization…
Apple’s free cash flow of $123.3B and a resilient hardware/services mix create a pragmatic bull case. Valuation is elevated but not extreme versus fundamentals; a tactical long with a $261 entry, $300 target and $230 stop balances upside from product catalysts and buybacks against macro and execution risks.
JPMorgan Chase (JPM) looks attractive as a long trade under $300. The bank trades at roughly 14x earnings with a 2%+ dividend yield, a healthy ROE and a large buyback/dividend capacity. Technicals show the name is oversold and below key moving averages, offering a defined entry with a clear stop and a realistic target near the 52-week high. This is…
Fair Isaac (FICO) reported earnings that underscore durable margins, strong free cash flow and an advantaged position in fraud, scoring and decisioning. The market sold off aggressively; that gap creates a low-risk entry for patient long-term traders. We upgrade our rating and lay out a concrete trade plan with a clear stop and targets.
Nexa Resources (NEXA) is a Latin American zinc miner and smelter trading at a modest multiple (PE ~11.7, PB ~1.55) with a market cap of $1.56B. The company’s integrated mining + smelting footprint gives it leverage to a cyclical recovery and operational improvements that can translate into visible free cash flow. We initiate an actionable trade: bu…
APA trades at a single-digit P/E and sub-2x P/B while generating roughly $1.8B of free cash flow. With improving momentum, a maintained $0.25 quarterly dividend and multiple near-term operational catalysts, I see asymmetric upside into $40 over the next 180 trading days with a tight stop at $28.
Byrna Technologies reported $118.1M in revenue for FY2025 (up 38% YoY) and remains a small-cap growth story trading near its 52-week low. With expanding retail distribution, production capacity increases, a planned marketing push and a still-modest valuation (market cap ~ $234M; EV/EBITDA ~ 15.8), there is a reasonable asymmetric opportunity for pa…
TSMC (TSM) has pulled back into the low $300s while demand from high-performance computing remains strong. Fundamentals and market share justify buying on a disciplined dip; this trade targets a retest of the 52-week high with a clearly defined stop.
Western Midstream (WES) offers an attractive entry for income-oriented investors: a 9%+ yield, strong free cash flow, and near-term catalysts in produced-water and data-center driven energy demand. Valuation is reasonable by cash-flow metrics and the balance sheet shows manageable liquidity. This trade idea outlines an actionable entry, stop, and t…
Unusual Machines (UMAC) is trading on a clear sentiment catalyst: accelerating revenue, a large cash balance and expanding addressable market from U.S. defense and regulatory shifts. The setup is actionable as a momentum swing trade while the company's fundamentals suggest a longer runway — but valuation is rich and execution risk is real. We outli…
Phase 3 data show ralinepag cuts clinical worsening by 55% and boosts improvement odds by 47%. With an NDA planned by mid-2026, a strong balance sheet, no debt and robust free cash flow position United Therapeutics to defend market share and valuation. We upgrade to a long with a clear entry, stop and target for a 180-trading-day horizon.
